Hybrid trials can further reduce patient burden

Patients as Partners EU 2022: How hybrid trials can further reduce patient burden

As the clinical research industry shifts into more accepted use of hybrid or decentralized clinical trials, a lot of questions still remain in the minds of research professionals looking to deploy modern study types of their own.

Join thought leaders in clinical research including Castor’s own Kimberly Tableman as they discuss how hybrid trials can further reduce patient burden through flexibility in protocol design and data generation.

Questions the panel will address:

What does it mean to truly be flexible in a hybrid trial environment?
Are regulators and the clinical healthcare ecosystem as a whole ready for additional flexibility created by hybrid clinical trials?
How do you organize yourself to facilitate for an investigator or a sponsor while maintaining control and oversight?